JF
Insider
James E Flynn
DirectorJames E Flynn (Director) filed 2 Form 4 reports in the trailing twelve months (1 purchase, 1 sale), most often in Larimar Therapeutics, Inc. (LRMR). Across 1 priced purchase filing, the average 21-session return was -16.6% from execution and -14.2% from disclosure (delay-adjusted; derived). The largest single filing was $70.9M of NUVL (742,574 sh across 2 lots, as filed), executed Nov 24 2025.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
-16.6%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
-14.2%
same 1 filings, from disclosure
Filings, ttm
2
1 buys · 1 sells
Median delay
3d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$95.9M
shares × price, as filed
Last traded
Feb 27
Filed Mar 2
Median ADV $8.5M across their filed names
Open performance→Volume by month
Buys $55.0M
Sells $84.5M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
2 filings
Sector per market data · by filing · past 12 months
Most traded names
LRMRRecent filings
LRMRPURCHASE
Larimar Therapeutics, Inc.
View filing →
$25.0M5,000,000 sh across 4 lots
Exec Feb 27
Filed Mar 2 · 7:46 PM ET NUVLSALE Nuvalent Inc View filing → $70.9M
742,574 sh across 2 lots
Exec Nov 24 2025
Filed Nov 24 2025 · 5:30 PM ET LRMRPURCHASE Larimar Therapeutics, Inc. View filing → $30.0M
9,375,000 sh across 3 lots
Exec Jul 31 2025
Filed Aug 4 2025 · 6:28 PM ET SPRYSALE ARS Pharmaceuticals, Inc. View filing → $13.7M
740,149 sh across 2 lots
Exec Jun 27 2025
Filed Jul 1 2025 · 5:30 PM ET